Literature DB >> 22138579

Adenosine A(2A) receptor ligation inhibits osteoclast formation.

Aránzazu Mediero1, Firas M Kara, Tuere Wilder, Bruce N Cronstein.   

Abstract

Adenosine is generated in increased concentrations at sites of injury/hypoxia and mediates a variety of physiological and pharmacological effects via G protein-coupled receptors (A(1), A(2A), A(2B), and A(3)). Because all adenosine receptors are expressed on osteoclasts, we determined the role of A(2A) receptor in the regulation of osteoclast differentiation. Differentiation and bone resorption were studied as the macrophage colony-stimulating factor-1-receptor activator of NF-κB ligand formation of multinucleated tartrate-resistant acid phosphatase (TRAP)-positive cells from primary murine bone marrow-derived precursors. A(2A) receptor and osteoclast marker expression levels were studied by RT-PCR. Cytokine secretion was assayed by enzyme-linked immunosorbent assay. In vivo examination of A(2A) knockout (KO)/control bones was determined by TRAP staining, micro-computed tomography, and electron microscopy. The A(2A) receptor agonist, CGS21680, inhibited osteoclast differentiation and function (half maximal inhibitory concentration, 50 nmol/L), increased the percentage of immature osteoclast precursors, and decreased IL-1β and tumor necrosis factor-α secretion, an effect that was reversed by the A(2A) antagonist, ZM241385. Cathepsin K and osteopontin mRNA expression increased in control and ZM241385-pretreated osteoclasts, and this was blocked by CGS21680. Micro-computed tomography of A(2A)KO mouse femurs showed a significantly decreased bone volume/trabecular bone volume ratio, decreased trabecular number, and increased trabecular space. A(2A)KO femurs showed an increased TRAP-positive osteoclast. Electron microscopy in A(2A)KO femurs showed marked osteoclast membrane folding and increased bone resorption. Thus, adenosine, acting via the A(2A) receptor, inhibits macrophage colony-stimulating factor-1-receptor activator of NF-κB ligand-stimulated osteoclast differentiation and may regulate bone turnover under conditions in which adenosine levels are elevated.
Copyright © 2012 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22138579      PMCID: PMC3349861          DOI: 10.1016/j.ajpath.2011.10.017

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  64 in total

1.  Adenosine A(2A) receptors are colocalized with and activate g(olf) in rat striatum.

Authors:  B Kull; P Svenningsson; B B Fredholm
Journal:  Mol Pharmacol       Date:  2000-10       Impact factor: 4.436

2.  Adenosine A(1) receptors regulate bone resorption in mice: adenosine A(1) receptor blockade or deletion increases bone density and prevents ovariectomy-induced bone loss in adenosine A(1) receptor-knockout mice.

Authors:  Firas M Kara; Stephen B Doty; Adele Boskey; Steven Goldring; Mone Zaidi; Bertil B Fredholm; Bruce N Cronstein
Journal:  Arthritis Rheum       Date:  2010-02

Review 3.  International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors--an update.

Authors:  Bertil B Fredholm; Adriaan P IJzerman; Kenneth A Jacobson; Joel Linden; Christa E Müller
Journal:  Pharmacol Rev       Date:  2011-02-08       Impact factor: 25.468

4.  Disruption of the A(3) adenosine receptor gene in mice and its effect on stimulated inflammatory cells.

Authors:  C A Salvatore; S L Tilley; A M Latour; D S Fletcher; B H Koller; M A Jacobson
Journal:  J Biol Chem       Date:  2000-02-11       Impact factor: 5.157

Review 5.  Methotrexate--how does it really work?

Authors:  Edwin S L Chan; Bruce N Cronstein
Journal:  Nat Rev Rheumatol       Date:  2010-03       Impact factor: 20.543

Review 6.  Bone resorption by osteoclasts.

Authors:  S L Teitelbaum
Journal:  Science       Date:  2000-09-01       Impact factor: 47.728

7.  IL-1 beta and TNF-alpha regulation of the adenosine receptor (A2A) expression: differential requirement for NF-kappa B binding to the proximal promoter.

Authors:  Silvana Morello; Kazuhiro Ito; Satoshi Yamamura; Kang-Yun Lee; Elen Jazrawi; Patricia Desouza; Peter Barnes; Carla Cicala; Ian M Adcock
Journal:  J Immunol       Date:  2006-11-15       Impact factor: 5.422

8.  Pathological role of osteoclast costimulation in arthritis-induced bone loss.

Authors:  Sae Ochi; Masahiro Shinohara; Kojiro Sato; Hans-Jürgen Gober; Takako Koga; Tatsuhiko Kodama; Toshiyuki Takai; Nobuyuki Miyasaka; Hiroshi Takayanagi
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-25       Impact factor: 11.205

9.  Molecular cloning and characterization of an adenosine receptor: the A3 adenosine receptor.

Authors:  Q Y Zhou; C Li; M E Olah; R A Johnson; G L Stiles; O Civelli
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

10.  cAMP/PKA regulates osteogenesis, adipogenesis and ratio of RANKL/OPG mRNA expression in mesenchymal stem cells by suppressing leptin.

Authors:  Der-Chih Yang; Huey-Jen Tsay; Shan-Yang Lin; Shih-Hwa Chiou; Mei-Jane Li; Tai-Jay Chang; Shih-Chieh Hung
Journal:  PLoS One       Date:  2008-02-06       Impact factor: 3.240

View more
  57 in total

1.  Adenosine A2A receptor activation prevents wear particle-induced osteolysis.

Authors:  Aránzazu Mediero; Sally R Frenkel; Tuere Wilder; Wenjie He; Amitabha Mazumder; Bruce N Cronstein
Journal:  Sci Transl Med       Date:  2012-05-23       Impact factor: 17.956

2.  Adenosine A1 receptor regulates osteoclast formation by altering TRAF6/TAK1 signaling.

Authors:  W He; B N Cronstein
Journal:  Purinergic Signal       Date:  2012-02-05       Impact factor: 3.765

3.  Does adenosine play a role in bone formation, resorption and repair?

Authors:  Bronwen A J Evans
Journal:  Purinergic Signal       Date:  2012-06       Impact factor: 3.765

Review 4.  Purinergic signalling in the musculoskeletal system.

Authors:  Geoffrey Burnstock; Timothy R Arnett; Isabel R Orriss
Journal:  Purinergic Signal       Date:  2013-08-14       Impact factor: 3.765

5.  Regeneration of a Pediatric Alveolar Cleft Model Using Three-Dimensionally Printed Bioceramic Scaffolds and Osteogenic Agents: Comparison of Dipyridamole and rhBMP-2.

Authors:  Christopher D Lopez; Paulo G Coelho; Lukasz Witek; Andrea Torroni; Michael I Greenberg; Dean L Cuadrado; Audrey M Guarino; Jonathan M Bekisz; Bruce N Cronstein; Roberto L Flores
Journal:  Plast Reconstr Surg       Date:  2019-08       Impact factor: 4.730

6.  Bone regeneration in critical bone defects using three-dimensionally printed β-tricalcium phosphate/hydroxyapatite scaffolds is enhanced by coating scaffolds with either dipyridamole or BMP-2.

Authors:  Stephanie Ishack; Aranzazu Mediero; Tuere Wilder; John L Ricci; Bruce N Cronstein
Journal:  J Biomed Mater Res B Appl Biomater       Date:  2015-10-29       Impact factor: 3.368

7.  Activation of EPAC1/2 is essential for osteoclast formation by modulating NFκB nuclear translocation and actin cytoskeleton rearrangements.

Authors:  Aránzazu Mediero; Miguel Perez-Aso; Bruce N Cronstein
Journal:  FASEB J       Date:  2014-08-13       Impact factor: 5.191

8.  Adenosine A2A receptor (A2AR) stimulation modulates expression of semaphorins 4D and 3A, regulators of bone homeostasis.

Authors:  Aránzazu Mediero; Tuere Wilder; Lopa Shah; Bruce N Cronstein
Journal:  FASEB J       Date:  2018-02-02       Impact factor: 5.191

9.  Netrin-1 is a critical autocrine/paracrine factor for osteoclast differentiation.

Authors:  Aránzazu Mediero; Bhama Ramkhelawon; Miguel Perez-Aso; Kathryn J Moore; Bruce N Cronstein
Journal:  J Bone Miner Res       Date:  2015-05       Impact factor: 6.741

Review 10.  Adenosine and bone metabolism.

Authors:  Aránzazu Mediero; Bruce N Cronstein
Journal:  Trends Endocrinol Metab       Date:  2013-03-14       Impact factor: 12.015

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.